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(O-GlcNAc). Previously, O-GlcNAcylation of a speciﬁc site of Sp1 was shown to inhibit Sp1 transcrip-
tional activity. Yet, how O-GlcNAc on other modiﬁcation sites affects Sp1 function and how O-GlcNA-
cylationof Sp1 affects the transcriptional regulation of a target gene remains unknown.Herewe show
that O-GlcNAc within the second serine/threonine-rich region of Sp1 interrupts a known interaction
between Sp1 and Oct1, and inhibits the cooperative activation of the U2 snRNA gene by Sp1 and Oct1.
Structured summary:
MINT-6803452: Sp1 (uniprotkb:P08047) physically interacts (MI:0218) with Oct1 (uniprotkb:P14859) by
anti tag coimmunoprecipitation (MI:0007)
MINT-6803426, MINT-6803438: Oct1 (uniprotkb:P14859) binds (MI:0407) to Sp1 (uniprotkb:P08047) by
pull down (MI:0096)
MINT-6803470, MINT-6803484: Sp1 (uniprotkb:P08047) physically interacts (MI:0218) with Oct1 (uni-
protkb:P14859) by anti bait coimmunoprecipitation (MI:0006)
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Since the discovery of O-linked N-acetylglucosamine (O-Glc-
NAc), monosaccharide N-acetylglucosamine addition to serine
and threonine residues of proteins, a myriad of nucleocytoplasmic
proteins bearing this modiﬁcation have been identiﬁed [1] and
important functions of O-GlcNAc have been unveiled, including
the regulation of 26S proteasome activity [2], stress resistance/re-
sponse [3,4] and signal transduction [5,6]. Among the possible
functions of O-GlcNAc that have been proposed, there is increasing
evidence for its involvement in gene regulation. O-GlcNAc re-
presses the transcriptional activity of Sp1 [7] and the expression
of nuclear hormone receptor genes [8]. O-GlcNAc transferase
(OGT), the enzyme that catalyzes the addition of O-GlcNAc, is re-
cruited onto promoters and thus may participate in gene silencing
by the O-GlcNAcylation of nearby proteins [9]. O-GlcNAc also con-
trols transcription by regulating the proteasomal susceptibility of
transcription regulatory proteins [2,8].
Sp1 is the ﬁrst protein to be identiﬁed as an O-GlcNAc protein
among transcription regulators, and it is estimated to harbor
multiple O-GlcNAc molecules [10]. There have been a few reportschemical Societies. Published by E
.to address functional roles of the Sp1 O-GlcNAcylation. O-GlcNAc
state of Sp1 is associated with its proteasomal susceptibility [11]
and also involved in the subcellular distribution of Sp1 [12]. O-Glc-
NAc on a modiﬁcation site within the second glutamine (Q)-rich
transactivation domain of Sp1 (484Ser of human Sp1, correspond-
ing to 493Ser of mouse Sp1 in this study) interrupts Sp1-dTAF110
interaction and Sp1 multimerization [7,13]. O-GlcNAcylation of
this site represses the transactivation capability of the Q-rich acti-
vation domain and increased O-GlcNAc inhibits Sp1 activation of a
promoter consisting of Sp1 binding motifs [7]. Here, we report that
most O-GlcNAc sites in Sp1 reside within its second serine/threo-
nine (S/T)-rich region, which is distal to the previously identiﬁed
site [7,13], and that the O-GlcNAc in this region inhibits the func-
tional interaction between Sp1 and Oct1.
2. Materials and methods
2.1. Plasmids and cloning
For the expression of glutathione S-transferase (GST)-fused Sp1
deletions in Escherichia coli, mouse Sp1 DNA fragments were
produced from pGEX-Sp1 [3] using PCR and subsequently inserted
into pGEX2T or pGEX-KG. Used primers are shown in Table 1. To
express Sp1 and its deletions as GST-fusions in mammalian cells,
GST-Sp1 fragments were produced from pGEX-Sp1 or pGEX-Sp1lsevier B.V. All rights reserved.
Table 1
PCR primers for Sp1 deletions.
Sp1N293 F 50-TCTGGTTCCGCGTGGATCC-30a
R 50-GCTGCTCTCCTGGGATCC-30
Sp1292–544/272–544 F292–544 50-CGGGATCCCAGGAGAGCAGC-30
F272–544 50-CGGAATTCAACAGCGTTTCTGCAGCT-30
R 50-GGCCTGGAAGCTGGTGCA-30
Sp1545C F 50-CGGGATCCCAGGTGCACCAGCTTCCA-30
R 50-GGAATTCTTGGACCCATGCTACCTTGCATCC-30
Sp1N551/N484/N356 FN293
RN551 50-GGAATTCGGCCAGGAAGCTGGTGCA-30
RN484 50-GGAATTCGTGATTGTCTGGGCTTGT-30
RN356 50-GGAATTCCTGGCCTTGAGAACTAGT-30
Sp1292–356 F 50-CGGGATCCCAGGAGAGCAGC-30
R 50-GGAATTCCTGGCCTTGAGAACTAGT-30
Sp1351–484 F 50-GGGATCCACTAGTTCTCAAGGCCAG-30
R 50-GGGATCCGTGATTGTCTGGGCTTGT-30
Sp1480–551 F 50-GGAATTCCAAGCCCAGACAATCACC-30
RN551
Sp1N306/N326/N343 F 50-TCTGGTTCCG CGTGGATC-30
RN306 50-GGAATTCGGCAGTCCCTGAGGTGAC-30
RN326 50-GGAATTCGGCATTGGTGAAAAAGGA-30
RN343 50-GGAATTCAAAGTTCATAATTCCCAT-30
Sp1338–484/321–484/300–484 F300–484 50-CGGGATCCGTCACCTCAGGGACTGCC-30
F321–484 50-CGGGATCCTCCTTTTTCACCACTGCC-30
F338–484 50-CGGGATCCATGGGAATTATGAACTTT-30
R 50-GGGATCCGTGATTGTCTGGGCTTGT-30
Sp1281–301 F 50-CCGGAATTCTACCCAGCTCTCAGGCAGGC-30
R 50-CCGGAATTCGACAGGCTGTGAGCTGCTC-30
Sp1300–326 F 50-CCGGAATTCTACCTGTCACCTCAGGGACTG-30
R 50-CCGGAATTCGGCATTGGTGAAAAAGGAGCTG-30
Underlined sequences are restriction enzyme sites used for cloning (GAATTC, EcoRI;
GGATCC, BamHI; AAGCTT, HindIII).
a Corresponds to the 917–934 region of pGEX vectors.
K. Lim, H.-I. Chang / FEBS Letters 583 (2009) 512–520 513deletions using PCR and inserted into pEGFP-C1. For the production
of site-directed or internally deleted mutant Sp1 molecules, Sp1
was subcloned into pUC19 and inverse PCR was performed using
50 phosphorylated primers (Table 2), and Sp1-encoding DNA was
cloned into the EcoRI site of pEGFP-C1-GST, which was constructed
by inserting a PCR-ampliﬁed GST fragment from pGEX-2T between
HindIII and EcoRI of pEGFP-C1 (primers were F 50-GGCGAAG-
CTTCGATGTCCCCTATACTAGGTTATTG-30 and R 50-GGCGAAGCTT-
CAGATCCGATTTTGGAGGA-30). To construct p(GC:Octa)-Luc, a
double-stranded oligonucleotide containing the 232 to 207 se-
quence of the U2 snRNA promoter and E1a viral TATA element was
inserted between BglII and HindIII of pGL3 basic luciferase reporter
plasmid: 50-GATCTAAAGGGCGGGGCATGCAAATTCGAAACTCGAG-
GGTATATAATGA-30 (Xho1 site is underlined). pTATA-Luc was
generated by removing the U2 snRNA promoter sequence from
p(GC:Octa)-Luc by XhoI digestion. For pHM6-OGT, OGT was PCR-
ampliﬁed with primers, F (50-GGCCCGCGGCCGCTAATGCTG-
CAGGGTCACTTTTGGCTGG-30) and R (50-GGCCCGCGGCCGCATTA-
TGCTGACTCAGTGACTTCAAC), and inserted into the Not1 site ofTable 2
PCR primers for Sp1 mutagenesis.
Sp1mut1 F 50-GCCATCAGTTCTGCCAGCTTG-30
R 50-GACAGGCTGTGAGCTGCTCTCCF-30
Sp1mut2 F 50-TTGGTGTCATCACAAGCTAGTTC-30
R 50-GATGGCAGTCCCTGAGGTGAC-30
Sp1 mut3 F 50-GGTGGCCAAGCTAGTTCCAGCTCCTTTTTCAC-30
R 50-CACCAAGCTGGCAGAACTGATG-30
Sp1 mut4 F 50-TTTTTCACCAATGCCAATAGTTATTC-30
R 50-GCTTGTGATGACACCAAGCTG-30
Sp1 mut5 F 50-GGCAATGCCAATAGTTATTCAACAACTAC-30
R 50-GAAAAAGGAGCTGGAACTAGC-30
Sp1 mut6 F 50-AACATGGGAATTATGAACTTTACCAG-30
R 50-ATTGGCATTGGTGAAAAAGGAG-30
Sp1D302–320/D302–337 F 50-GACAGGCTGTGAGCTGCTCTC-30
R D302–320 50-TCCTTTTTCACCAATGCC-30
R D302–337 50-ATGGGAATTATGAACTTTACC-30pHM6. pHM6-O-GlcNAcase (OGA) and pcDNA3-myc-Sp1 were pre-
viously described [3].
2.2. In vitro pull-down assay
Approximately 2–5 lg of GST- or histidine-tagged proteins
immobilized on glutathione beads or nickel-chelating beads were
incubated with their binding partner proteins (10–20 lg) in a
binding buffer [14] at 4 C for 1 h. The bound and unbound frac-
tions were subjected to immunoblotting.
2.3. Coimmunoprecipitation
Cells on the culture dishes were washed with PBS twice and
incubated with 1 mM dithiobis[succinimidylpropionate] (DSP) for
30 min. DSP is a cell-permeable crosslinker used to covalently join
closely positioned proteins and cleavable by reducing reagents,
thereby stabilizes protein complexes [15]. After DSP was quenched
by incubation in TBS for 10 min, cells were harvested by scrapping.
Immunoprecipitation from either the nuclear extracts or the whole
cell lysates was performed using ExtraCruz IP/Western blot re-
agent F (sc-45043; Santa Cruz, USA) according to the manufac-
turer’s instructions.
2.4. DNA binding assay
Twenty nmol of biotinylated double-stranded oligonucleotides
(GC:Octa, 50-AACCAAAGGGCGGGGCATGCAAATTCGAAA-30; AP1,
50-CGCTTGATGAGTCAGCCGGAA-30) were immobilized on 250 ll
of streptavidin-agarose beads (Sigma, USA) in binding buffer
(10 mM HEPES-NaOH, pH 7.5, 75 mM NaCl, 1 mM MgCl2, 0.1%
NP-40, 5% glycerol) containing 1 mM EDTA at 4 C overnight. One
hundred microliters of DNA-immobilized beads was incubated
with saturating levels of Sp1 and Oct1, which were produced from
E. coli, for 1 h and then washed with the binding buffer. For compe-
tition, 20 ll of prepared beads was incubated with the indicated
amounts of free oligonucleotide probes in 300 ll of the binding
buffer at 4 C with agitation (Sp1 binding consensus DNA [GC] 50-
ATTCGATCGGGGCGGGGCGAGC-30, Oct1 binding consensus DNA
[Octa] 50-TGTCGAATGCAAATCACTAGAA-30, AP1 50-CGCTTGAT-
GAGTCAGCCGGAA-30). Thirty minutes later, the beads were
washed and bound proteins were eluted with Laemmli sample buf-
fer containing 300 mM NaCl. The experiment was performed in
triplicate and the means ± S.D. was presented.
2.5. Luciferase reporter assay
293 or Huh7 cells in 24 wells or 12 wells were transfected with
the indicated plasmids for 42–48 h together with pCMV-b-galacto-
sidase (pCMV b-gal) as an internal control. The luciferase assays
were performed as previously described [3].Table 3
PCR primers for (semi) quantitative RT-PCR.
U2 snRNA (1–181) F 50-ATCGCTTCTCGGCCTTTTGGCTAAG-30
R 50-ACCGTTCCTGGACCTACTGCAATAC-30
b-Actin (403–876) F 50-CTATCCAGGCTGTGCTATCCCTGTAC-30
R 50-CCCAGGAAGGAAGGCTGGAAG-30
Sp1 (2185–2440)a F 50-TGGGGCAGGTTCAGAAGGCA-30
R 50-GAAACCATTGCCACTGATATTAATG-30
OGT (2907–3024) F 50-TGCTAAAAACAGACAAGAATATGAAGACATAG-30
R 50-GTTGAACAGAGGGCTAGATATTCTTTGC-30
OGA (2180–2444)a F 50-CCGTGTACAAGATTTGCAGAGAAATG-30
R 50-CTCAGCCTCAGAGAGTTCCTTGTCAC-30
OGT, O-GlcNAc transferase; OGA, O-GlcNAcase.
a Primers for Sp1 and OGA are speciﬁc for both mouse and human transcripts.
Fig. 1. O-GlcNAc modiﬁcation sites on Sp1. (A) Schematic diagrams of Sp1 deletions. S/T, serine/threonine-rich region; Q, glutamine-rich transactivation domain; DBD, DNA
binding domain; GST, glutathione S-transferase. The arrow head indicates a previously identiﬁed O-GlcNAc site. The + and  on the right indicate the glycosylated and
unglycosylated proteins, respectively. The amino acid sequence of the second S/T-rich region of Sp1 (BS/T) is shown (lower). Mutant 1, 2, 4, 6, Sp1D302–320 and Sp1D302–337
were generated by deletion of the indicated regions and mutant 3 and 5 were generated by substituting serine and threonine with glycine. The + and  indicate the
glycosylated and unglycosylated sites, respectively. (B, C) GST-Sp1 (B) or GST-Sp1 deletions (C) were coexpressed with O-GlcNAc transferase (OGT) in E. coli and puriﬁed using
glutathione beads. O-GlcNAc proteins were detected by O-GlcNAc immunoblotting with CTD110.6 antibody. GST-Sp1 proteins were revealed by immunoblotting with anti-
GST antibody or by Ponceu S staining. The lane numbers correspond to the Sp1 deletions shown in (A). (D) pEGFP-C1 constructs encoding GST-Sp1 deletions were transfected
into 293 cells. GST-Sp1 proteins were puriﬁed and analyzed by immunoblotting. CTD110.6-speciﬁc bands were indicated with asterisks (bands in the other lanes are
considered as O-GlcNAc proteins non-speciﬁcally co-precipitated with beads). (E, F) pEGFP-C1 constructs encoding mutant Sp1 proteins were transfected into 293 cells and
analyzed as in (D). O-GlcNAc levels of Sp1 proteins were measured by densitometry of anti-O-GlcNAc blots and normalized by Sp1 polypeptide levels. The O-GlcNAc levels of
the mutant Sp1 proteins were expressed as a percentage of wild type Sp1 (Sp1w).
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Fig. 2. O-GlcNAc inhibits Sp1–Oct1 interaction in vitro. (A) O-GlcNAcylated full length GST-Sp1 (Sp1FL) and -Sp1 B-domain (Sp1B) were produced as described in Fig. 1B,
from which Sp1FL and Sp1B were obtained by thrombin cleavage. Sp1FL was stained with Coomassie brilliant blue (CBB) and Sp1B was visualized by Sp1 immunoblotting.
Histidine-tagged Oct1 (His-Oct1) and Oct1 (which was obtained by thrombin cleavage of His-Oct1) were stained with CBB and the removal of histidine-tag was conﬁrmed by
immunoblotting using anti-polyhistidine antibody. Sup, supernatant. (B) His-Oct1 immobilized on beads was incubated with O-GlcNAcylated Sp1FL or Sp1B. The bound (B)
and unbound (UB) fractions were analyzed by immunoblotting. (C) His-Sp1 and His-O-GlcNAcylated Sp1 immobilized on beads were incubated with Oct1, which was
obtained by thrombin cleavage of His-Oct1, and the bound proteins were analyzed by immunoblotting.
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293 cells (six wells) were transfected with the indicated plas-
mids for 42 h and total RNA was prepared. cDNA was synthesized
by reverse transcription (RT) from the total RNA using oligo (dT)18
and U2 snRNA reverse primer (Table 3). For semi-quantitative RT-
PCR, PCR was performed in a total volume of 50 ll using 2–4 ll of
the diluted RT products as follows: U2 snRNA (95 C for 15 s, 56 C
for 15 s, 72 C for 10 s), b-actin (95 C for 15 s, 53 C for 15 s, 72 C
for 30 s), Sp1 (95 C for 15 s, 57 C for 15 s, 72 C for 10 s), OGT
(95 C for 15 s, 54 C for 15 s, 72 C for 10 s) and OGA (95 C for
15 s, 50 C for 15 s, 72 C for 15 s). Used primers are shown in Table
3. The PCR products were visualized by ethidium bromide staining
on a 2% agarose gel. Quantitative RT-PCR was also performed to
measure the relative transcript levels using a Lightcycler 480 sys-
tem (Roche, Germany) and SYBER green reagent (Bioneer, Korea)
according to the manufacturer’s instructions. U2 snRNA levels
were normalized against the b-actin mRNA. Each experiment was
repeated at least three times and PCR from each transfection was
repeated at least twice in triplicate.
3. Results and discussion
3.1. O-GlcNAc modiﬁcation of the second serine/threonine-rich region
of Sp1
To localize the O-GlcNAc modiﬁcation sites in Sp1, we con-
structed a series of GST-fused Sp1 deletions (Fig. 1A) and coexpres-
sed them along with OGT in E. coli. As shown in Fig. 1B,
coexpressed OGT efﬁciently O-GlcNAcylated Sp1in E.coli as previ-
ously reported [3]. The GST-Sp1 deletions were then puriﬁed using
glutathione agarose beads and subjected to O-GlcNAc immuno-
blotting. The results showed that the second S/T-rich region of
Sp1 (BS/T) was efﬁciently glycosylated (Fig. 1C). In order to conﬁrm
O-GlcNAcylation of Sp1 BS/T in mammalian cells, we constructed
pEGFP-C1 plasmids encoding GST-Sp1 deletions and transfectedthem into 293 cells. In these pEGFP-C1 constructs, GST-Sp1 pro-
teins were further fused to a green ﬂuorescent protein (GFP) in
their N-terminus. GFP-GST-Sp1 deletions were puriﬁed using glu-
tathione agarose beads and analyzed by O-GlcNAc immunoblot-
ting. The results also showed that Sp1 BS/T was efﬁciently O-
GlcNAcylated in 293 cells consistent to the result in Fig. 1C. To fur-
ther locate O-GlcNAc sites within the BS/T region, serine and thre-
onine residues in the S/T-rich region were either substituted or
deleted (Fig. 1A), and the GST-Sp1 mutants were expressed in
293 cells. O-GlcNAc immunoblot analysis of the Sp1 mutants re-
vealed that multiple serine or threonine residues throughout this
region could be O-GlcNAcylated (Fig. 1E), and this ﬁnding was fur-
ther conﬁrmed by the observation that the internal deletion of this
region signiﬁcantly reduced the O-GlcNAc levels of Sp1 (Fig. 1F).
These results indicate that the majority of Sp1 O-GlcNAc sites re-
side within its second S/T-rich region. Interestingly, the O-glycosyl-
ation level of Sp1D328–335 (mut6) was drastically reduced
compared with other point and deletion mutants. The serine/thre-
onine stretch spanning 328–335 amino acids may be multiply
modiﬁed by O-GlcNAc or may be a primary recognition/modiﬁca-
tion site by OGT, subsequently affecting O-GlcNAc modiﬁcation
of adjacent sites.
3.2. O-GlcNAc modiﬁcation of Sp1 inhibits the interaction between Sp1
and Oct1
Sp1 interacts with Oct1, a POU domain-containing transcription
factor, via its second transactivation domain (BQ) and the S/T-rich
region (BS/T) [14], which was found to be O-GlcNAcylated. There-
fore, we investigated whether the O-GlcNAc of Sp1 would affect
the interaction of Sp1 and Oct1. We ﬁrst performed in vitro
pull-down assays using recombinant proteins produced from
E. coli (Fig. 2A). Oct1 was immobilized on beads and incubated with
O-GlcNAcylated full length Sp1(Sp1FL) or Sp1 B-domain (Sp1B)
(in fact, a mixture of modiﬁed and unmodiﬁed forms). Immuno-
blot analysis of the bound and unbound fractions showed that
Fig. 3. O-GlcNAc inhibits Sp1–Oct1 interaction in vivo. (A) 293 cells were transfected with pcDNA3-myc (empty), pcDNA3-myc-Sp1w, or -Sp1D328–335 and myc-Sp1 proteins
were immunoprecipitated using anti-myc antibody. The precipitated fractions were analyzed by immunoblotting with the indicated antibodies. IP, immunoprecipitation.
Protein levels were measured by densitometry of immunoblots and the levels of coimmunoprecipitated Oct1 and O-GlcNAc levels of Sp1 were normalized against Sp1
polypeptide levels. The level of Oct1 coimmunoprecipitated with Sp1D328–335 and O-GlcNAc level of Sp1D328–335 were expressed as a fold change of those of Sp1w. (B) Huh7
cells were treated with or without 0.1 mM 6-diazo-5-oxonorleucine (DON) or 0.1 mM DON plus 2 mM glucosamine (GlcN) for 30 h. Total cell extracts were then prepared and
Sp1 was immunoprecipitated. Sp1 polypeptide levels and their O-GlcNAc levels were revealed by immunoblotting. NE, nuclear extract. (C, D) From the nuclear extracts of
Huh7 cells treated as in (B), Sp1 or Oct1 was immunoprecipitated and the precipitated fractions were analyzed by immunoblotting using the indicated antibodies. The levels
of coimmunoprecipitated Oct1 (normalized by Sp1) and Sp1 (normalized by Oct1) from Huh7 cells treated as indicated were measured by densitometry and expressed as a
percent of those not treated.
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(Fig. 2B). When Sp1 was immobilized, Oct1 consistently bound to
unmodiﬁed Sp1 more efﬁciently than to O-GlcNAcylated Sp1
(Fig. 2C), suggesting that O-GlcNAc blocks the Sp1–Oct1
association.We next performed a series of Sp1–Oct1 coimmunoprecipita-
tion assays in order to assess whether O-GlcNAc in Sp1 BS/T inhibits
Sp1–Oct1 association in vivo. Myc-tagged wild-type Sp1 (Sp1w)
and Sp1D328–335 were transfected into 293 cells and immunopre-
cipitated using myc antibody. Immunoblot analysis of the immu-
Fig. 4. O-GlcNAc inhibits the Sp1–Oct1 cooperative binding to U2 snRNA promoter. (A) Sp1 or O-GlcNAcylated Sp1 was incubated with the distal element sequence (GC:Octa,
232 to 207 of U2snRNA promoter)-immobilized beads. Sp1-bound beads were incubated with a free oligonucleotide containing Sp1-binding sequence (GC) at the
indicated concentrations. Sp1 that remained bound was visualized by immunoblotting, and the Sp1 levels were measured by densitometry. The Sp1 levels were expressed as
a percent of those competed by a non-speciﬁc probe, AP1. (B, C) Both Sp1 and Oct1 were made to bind to GC:Octa-immobilized beads, followed by incubation with a free
oligonucleotide containing Oct1-binding sequence (Octa) and Sp1-binding sequence (GC) as competitors, or AP1-binding sequence (AP1) as a non-speciﬁc competitor. Bound
Oct1 and Sp1 levels after the incubation with competitors, which were normalized by the levels of the counterpart proteins, were expressed as a percent of those competed by
AP1. Each experiment was repeated three times.
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signiﬁcantly higher amount of Oct1 than Sp1w did (Fig. 3A). This
result indicates that O-GlcNAc in the second S/T region of Sp1
interrupts Sp1–Oct1 interaction. We also found that the formation
of the endogenous Sp1–Oct1 complex was interrupted by O-Glc-
NAc. Diazo-5-oxonorleucine (DON), which inhibits UDP-GlcNAc
biosynthesis, reduces O-GlcNAc levels of Sp1, which are restored
by glucosamine in Huh7 cells (Fig. 3B). Thus, we attempted Sp1–
Oct1 coimmunoprecipitation in Huh7 cells whose O-GlcNAc levels
were manipulated by DON and glucosamine. The Oct1 level in Sp1
immunoprecipitates and the Sp1 level in Oct1 immunoprecipitates
from DON-treated cells were detectably higher than those from
cells left untreated or treated with DON plus glucosamine
(Fig. 3C and D). Taken together, these data indicate that O-GlcNAc
of Sp1 interrupts the physical interaction between Sp1 and Oct1.
3.3. O-GlcNAc inhibits the cooperative activation of U2 snRNA
transcription by Sp1 and Oct1
The U2 snRNA gene is transcribed by RNA polymerase II, and its
promoter contains an essential enhancer, distal sequence element
(DSE), which contains Sp1 and Oct1 sites [16]. The cooperative
occupancy and synergistic activation of the DSE by Sp1 and Oct1
are essential for U2 snRNA transcription [14,16]. Thus, we investi-
gated how the interruption of the Sp1–Oct1 association by O-Glc-
NAc would affect the transcription of U2 snRNA genes. We ﬁrst
tested if O-GlcNAc could inhibit the cooperative binding of Sp1
and Oct1 to the DSE. The biotinylated DSE oligonucleotide (GC:Oc-
ta, 232 to 207 of U2 snRNA promoter; Fig. 5A) was immobilized
on streptavidin-agarose beads, to which Sp1 and Oct1 were made
to bind. The beads were then incubated with a free probe contain-
ing Sp1-binding (GC) or Oct1-binding sequence (Octa) at variable
concentrations as a competitor or AP1-binding sequence (AP1) asa non-speciﬁc competitor, and the proteins that remained bound
to the beads were analyzed by immunoblotting. At ﬁrst, the DNA
binding activities of Sp1 and O-GlcNAcylated Sp1 alone were sim-
ilar (Fig. 4A). However, when the ternary complexes composed of
Sp1, Oct1 and GC:Octa were challenged by free GC or Octa probe,
both Sp1 and Oct1 from the unmodiﬁed Sp1-containing complex
resisted dissociation from the complex relatively stronger than
those from the O-GlcNAcylated Sp1-containing complex did
(Fig. 4B and C), which indicates that O-GlcNAc inhibits the Sp1–
Oct1 interaction not only in solution but also while they are bind-
ing to DNA. In order to further conﬁrm in vitro results in Fig. 4, we
conducted chromatin immunoprecipitation (ChIP) assays using
streptozotocin, an OGA inhibitor that increases O-GlcNAc levels,
and found that both Sp1 and Oct1 occupancy of the GC:Octa ele-
ment in the U2 snRNA promoter was suppressed in streptozoto-
cin-treated cells (data not shown). However, a ﬁnal conclusion of
this could be made by ChIP assays using more speciﬁc inhibitors
or siRNA-mediated knock-down of O-GlcNAc modifying enzymes.
We next performed reporter assays with a reporter plasmid,
p(GC:Octa)-Luc, in which the luciferase gene was driven by the
GC:Octa element (Fig. 5A). To conﬁrm the GC-Octa cooperativity,
GC and Octa were individually mutated (Fig. 5A) and their tran-
scription activities were examined. As expected, the mutation of
either GC or Octa almost completely abolished the transcription
activity of the whole element (Fig. 5B). Previously, OGT overex-
pression was shown to inhibit the Sp1 activation of a GC-driven
promoter [7]. Similarly, we conducted reporter assays by cotrans-
fection of p(GC:Octa)-Luc together with OGT or O-GlcNAcase
(OGA). As shown in Fig. 5C, the overexpression of OGT reduced
while the overexpression of OGA elevated the luciferase activities.
Given the observation that OGT increased and OGA decreased O-
GlcNAc levels of Sp1 and cellular proteins (Fig. 5D), the results sug-
gest the possibility that O-GlcNAcylation of Sp1 inhibits transcrip-
Fig. 5. O-GlcNAc inhibits the Sp1–Oct1 cooperative activation of the U2 snRNA promoter. (A) Luciferase reporters containing GC:Octa element of U2 snRNA promoter. The
underlined regions are Sp1 (left) and Oct1 (right) binding motifs. GCm:Octa and GC:Octam indicate the constructs containing mutated GC and Octa element, respectively. (B)
Indicated reporters (0.2 lg) were transfected into 293 cells together with pCMV-b-gal as an internal control for 42 h and luciferase assays were performed. The luciferase
activities were normalized by b-gal activities and the means ± S.D. from triplicate assays were presented. RLU, relative luciferase unit; b-gal, b-galactosidase. (C) p(GC:Octa)-
Luc was cotransfected into 293 cells together with pHM6-OGT or -OGA and pCMV-b-gal for 42 h and luciferase assays were performed as above. (D) 293 cells were transfected
with 35 lg of pHM6 (Empty), pHM6-OGT or –OGA for 48 h and Sp1 was immunoprecipitated. Immunoprecipitated Sp1 and total lysates (15 lg) were subjected to
immunoblotting using the indicated antibodies. Haemagglutinin (HA)-tagged OGT and OGA were detected by immunoblotting of the total lysates using HA antibody. (E)
p(GC:Octa)-Luc (1 lg) was transfected into Huh7 cells for 8 h. Cells were then treated with DON alone or DON plus glucosamine further for 24 h. The luciferase activities from
the identical amounts of cell extracts were measured and the means ± S.D. from triplicate assays were presented. In parallel with the luciferase assays, Sp1 proteins from each
treatment were immunoprecipitated and their O-GlcNAc levels were revealed by immunoblotting. The O-GlcNAc levels of Sp1, which were normalized by Sp1 polypeptide
levels, from each treatment were measured by densitometry and presented as a percent of those from non-treatment. (F, G) 293 cells were cotransfected with p(GC:Octa)-Luc,
plasmid constructs encoding the indicated proteins and pCMV-b-gal, and luciferase assays were performed as above. Luciferase activities were normalized against b-gal
activities and the means ± S.D. from triplicate assays were shown. The expression of transfected Sp1 proteins and the levels of total Sp1 and Oct1 proteins were monitored by
immunoblotting of the cell extracts used in luciferase assays.
518 K. Lim, H.-I. Chang / FEBS Letters 583 (2009) 512–520tion of the GC:Octa element. To further conﬁrm this, Huh7 cells
were transfected with p(GC:Octa)-Luc and then treated with
DON alone or DON plus glucosamine. The luciferase assays re-
vealed that DON increased the expression of p(GC:Octa)-Luc, while
glucosamine debilitated the effect by DON (Fig. 5E). We also exam-
ined O-GlcNAc levels of Sp1 by O-GlcNAc immunoblotting of Sp1
immunoprecipitates from Huh7 cells that were treated with DON
and glucosamine identically in the luciferase reporter assays and
found that O-GlcNAc levels of Sp1 were inversely related to results
from the reporter assays. To speciﬁcally investigate the effect of O-
GlcNAcylation on Sp1, p(GC:Octa)-Luc was co-transfected with
Sp1w or Sp1D328–335 and luciferase assays were performed. As
shown in Fig. 5F, Sp1D328–335 elevated the luciferase activity higher
than Sp1w, suggesting that O-GlcNAc in the second S/T region of
Sp1 exerts an inhibitory function in the Sp1 transcriptional activa-tion of the GC:Octa element. To better see the relative levels of
transfected Sp1 and endogenous Sp1 species, we also performed
the reporter assays using GST-Sp1, which could be separated from
endogenous Sp1 on an immunoblot. The result also showed that
GST-Sp1D328–335 activated GC:Octa stronger than GST-Sp1w but
we found that the expression of endogenous Sp1 was signiﬁcantly
enhanced by the Sp1 transfection (Fig. 5G). It is likely that this in-
crease of endogenous Sp1 also contributed to the elevation of the
luciferase expression.
We next examined the effects on the transcription of endoge-
nous U2 snRNA genes by O-GlcNAc using quantitative RT-PCR.
Prior to quantitative PCR, we performed PCR manually in order
to conﬁrm the speciﬁc PCR ampliﬁcation of U2 snRNA and b-actin
as a control as well as the overexpression of OGT, OGA, and Sp1
(Fig. 6A, C, and E). Consistent with the ﬁndings from the reporter
Fig. 5 (continued)
K. Lim, H.-I. Chang / FEBS Letters 583 (2009) 512–520 519assays, the quantitative RT-PCR results demonstrated that the tran-
scription of the endogenous U2 snRNA genes was reduced by OGT
overexpression (Fig. 6B) but elevated by OGA overexpressionFig. 6. O-GlcNAc inhibits the transcription of endogenous U2 snRNA genes. 293 cells were
of the indicated genes were analyzed by semi-quantitative RT-PCR (A, C) and quantitative
conﬁrmed by agarose gel electrophoresis of their ampliﬁed products from RT-PCR. Th
transfection of the indicated effectors were expressed as a percentage of those by empt(Fig. 6D). Furthermore, overexpression of Sp1D328–335 activated
transcription of U2 snRNA genes stronger than Sp1w (Fig. 6E) con-
sistent to the reporter assays. Taken together, these results showtransfected with plasmids encoding the indicated proteins, and the transcript levels
RT-PCR (B, D, E). The overexpression of transfected OGT (A), OGA (C) and Sp1 (E) was
e levels of U2 snRNA transcripts, which were normalized by b-actin or Sp1, by
y vector transfection (B, D, E).
520 K. Lim, H.-I. Chang / FEBS Letters 583 (2009) 512–520that the O-GlcNAc modiﬁcation of Sp1, speciﬁcally of its BS/T
region, suppresses the cooperative activation of the U2 snRNA
promoter by Sp1 and Oct1.
The functions of Sp1 domains have been characterized in detail
[17], but little is known about its S/T-rich regions. In the present
study, we showed that the second S/T-rich region of Sp1 is the ma-
jor target region of O-GlcNAc modiﬁcation and O-GlcNAcylation of
this region affects the formation of Sp1–Oct1 complex. While Oct1
was reported to be O-GlcNAcylated in a previous study [18], we
could not detect O-GlcNAc of Oct1 either by OGT coexpression
with Oct1 in E. coli or O-GlcNAc immunoblot of Oct1 immunopre-
cipitate (data now shown), thus whether the Oct1 O-GlcNAcylation
affects the Sp1–Oct1 interaction is left undetermined in this study.
In the other hand, it has been reported that O-GlcNAc affects pro-
tein phosphorylation or vice versa [19,20]. Sp1 is a phosphoprotein
and Sp1 phosphorylation is known to be involved in its transcrip-
tion activation process [21,22]. The BS/T region of Sp1 contains
many possible phosphorylation sites and, if it is phosphorylated in-
deed, O-GlcNAc and phosphorylation may interplay to regulate Sp1
functions.
It seems that O-GlcNAc can profoundly affect gene expression
[2,7,8]. However, whether O-GlcNAc is a positive or negative signal
for gene expression remains unclear. O-GlcNAc inhibits the physi-
cal interaction of Sp1 and dTAF110 [13], Sp1 multimerization and
Sp1-driven transcription [7]. On the other hand, the CREB-binding
protein preferentially binds to glycosylated Stat5 [23]. O-GlcNAc
facilitates the Sp1-mediated transcription of PAI-1 [24] and NF-
rB-involved transcription of vascular cell adhesion molecule 1
[25]. It is possible that O-GlcNAc might affect gene expression in
a gene-speciﬁc manner [1,8]. This study provides further evidence
that O-GlcNAc acts as a negative regulator of gene expression and
suggests the possibility that O-GlcNAc can affect transcription of a
speciﬁc gene by modulating the interactions between the involved
activators.
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